Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,307,928 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and June 24, 2022, to the Vaccine Adverse Event Reporting System (VAERS). That’s an increase of 6,666 adverse events over the previous week.

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 29,162 reports of deaths — an increase of 131 over the previous week — and 241,226 serious injuries, including deaths, during the same time period — up 1,004 compared with the previous week.

Of the 29,162 reported deaths, 18,885 cases are attributed to Pfizer’s COVID-19 vaccine, 7,673 cases to Moderna and 2,537 cases to Johnson & Johnson (J&J).

Excluding “foreign reports” to VAERS, 837,192 adverse events, including 13,463 deaths and 84,965 serious injuries, were reported in the U.S. between Dec. 14, 2020, and June 24, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 13,463 U.S. deaths reported as of June 22, 16% occurred within 24 hours of vaccination, 20% occurred within 48 hours of vaccination and 58% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.

In the U.S., 593 million COVID-19 vaccine doses had been administered as of June 22, including 350 million doses of Pfizer, 224 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).

vaers data vaccine injury july 1

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

U.S. VAERS data from Dec. 14, 2020, to June 24, 2022, for 6-month-olds to 5-year-olds show:

U.S. VAERS data from Dec. 14, 2020, to June 24, 2022, for 5- to 11-year-olds show:

The most recent reported death (VAERS I.D. 2327226 ) occurred in an 8-year-old female from Texas who developed MIS-C [multi-system inflammatory syndrome] within one month of receiving her second dose of Pfizer.

Her VAERS report states:

“She developed inflamed lymph nodes (lymphadenitis), all over the body rash, ongoing fever for more than 3 weeks. She was diagnosed with MIS-C, her heart, intestines, lungs, skin and liver were inflamed. She was hospitalized and treated with immunoglobulin, steroids, anticoagulants, fever-reducing medications, etc. By the second treatment, her belly started getting distended, her lungs were filled with liquids. She was transferred to ICU and her heart stopped beating right there.”

  • 23 reports of myocarditis and pericarditis.The Defender has noticed over previous weeks that reports of myocarditis and pericarditis have been removed by the CDC from the VAERS system in this age group. No explanation was provided.

U.S. VAERS data from Dec. 14, 2020, to June 24, 2022, for 12- to 17-year-olds show:

  • 62 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 97% of cases attributed to Pfizer’s vaccine.

There was one less case reported attributed to Pfizer’s vaccine since the previous week.

  • 166 reports of blood clotting disorders with all cases attributed to Pfizer. VAERS reported 167 cases of blood clotting disorders in the 12- to 17-year-old age group last week.
  • 20 cases of postural orthostatic tachycardia syndrome (POTS) with all cases attributed to Pfizer’s vaccine.

U.S. VAERS data from Dec. 14, 2020, to June 24, 2022, for all age groups combined, show:

FDA advises COVID vaccine manufacturers to make new boosters targeting Omicron subvariants

The FDA on Thursday advised COVID-19 vaccine manufacturers to produce an updated booster vaccine targeting Omicron subvariants for this fall.

Following a vote by the agency’s vaccine advisory panel, the FDA advised manufacturers seeking to update current COVID-19 vaccines that they should “develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two-component (bivalent) booster vaccine so that the modified vaccines can potentially be used starting in early to mid-fall 2022.”

According to the FDA, vaccine manufacturers already reported data from clinical trials using Omicron BA.1, but will have to submit their data to the FDA prior to its evaluation of any potential authorization of a modified vaccine containing the omicron BA.4 and BA.5 component.

Although there have been no clinical trials to date testing modified vaccines with Omicron subvariants in humans, the agency said manufacturers “will also be asked to begin clinical trials with modified vaccines containing an omicron BA.4/5 component, as these data will be of use as the pandemic further evolves.”

The agency said it expects this year to be a “transitional period” when a modified booster vaccine may be introduced and is not recommending a change to the primary series vaccine at this time.

The FDA said current COVID-19 vaccines based on the original Wuhan strain — that is no longer circulating — provides a “base of protection against serious outcomes of COVID-19 caused by circulating strains of SARS-CoV-2.”

The FDA’s vaccine advisory panel on Tuesday voted 19 to 2 to recommend new COVID-19 booster shots that include the Omicron variant this fall.

The panel did not vote Tuesday on whether additional data would be needed to recommend an updated composition of the primary-series vaccines authorized for emergency use in the U.S., or whether it would be appropriate to continue to use a primary-series vaccine as a booster.

The meeting marked the first time the panel suggested vaccine makers modify their vaccines to target a different variant.

At the beginning of the meeting, Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, suggested a newly designed shot could begin in October, adding that it takes manufacturers around three months to choose a vaccine design and begin producing doses.

Biden inks $3.2 billion deal with Pfizer for 105 million doses of COVID vaccines

The Biden Administration on Wednesday announced it signed a $3.2 billion deal to purchase 105 million doses of Pfizer’s COVID-19 vaccine for a fall vaccination campaign, with options to buy up to 300 million doses.

The contract includes a combination of adult and pediatric doses, as well as supplies of a re-formulated COVID-19 booster shot that will contain the original variant and BA.4 and BA.5 Omicron subvariants.

The announcement from the White House that it had entered into a contract with Pfizer to include the modified boosters targeting the subvariants was made before the FDA announced it had advised pharmaceutical companies that boosters should be modified to include the Omicron subvariants.

The $3.2 billion dollars used to fund the campaign comes directly from U.S. taxpayers, who also paid $1.95 billion for the original 100 million doses obtained under Operation Warp Speed, and $19.50 per dose for 500 million more doses obtained through the government’s option contract.

Pfizer, Moderna shots more likely to cause serious injury than reduce risk of COVID-related hospitalization

A new analysis of Pfizer and Moderna COVID-19 vaccine trial data shows the risk of serious injury following the vaccine is greater than the reduction in COVID-19 hospitalizations, according to a study posted June 23 on Social Science Research Network.

“Combining the trials, there was a 43% increased risk of serious adverse events of special interest and an absolute risk increase of 12.5 serious adverse events of special interest per 10,000 vaccinated participants,” the authors of the pre-print paper wrote.

Based on their findings, the authors called for a harm-benefit analysis of COVID-19 vaccines.

The researchers, including Peter Doshi, Ph.D., senior editor at The BMJ and associate professor of pharmaceutical health services research at the University of Maryland School of Pharmacy concluded:

“A systematic review and meta-analysis using individual participant data should be undertaken to address questions of harm-benefit in various demographic subgroups. Full transparency of the COVID-19 vaccine clinical trial data is needed to properly evaluate these questions. Unfortunately, well over a year after widespread use of COVID-19 vaccines, participant-level data remain inaccessible.”

Fauci experiences COVID rebound after taking Paxlovid

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID) and chief medical advisor to President Biden, said Tuesday he is experiencing a rebound of COVID-19 symptoms after taking Paxlovid, Pfizer’s COVID-19 antiviral pill, Bloomberg reported.

Fauci tested positive for COVID-19 on June 15, despite being quadruple-vaccinated, initially experiencing “mild symptoms,” according to the NIAID.

Due to his age — 81 — which put him at high risk for developing complications, Fauci was prescribed Paxlovid.

The drug, which is made from a combination of nirmatrelvir and ritonavir, in December 2021 was granted Emergency Use Authorization to treat COVID-19.

“After I finished the five days of Paxlovid, I reverted to negative on an antigen test for three days in a row,” Fauci said Tuesday in a remote interview during the Foreign Policy’s Global Health Forum.

“And then on the fourth day, just to be absolutely certain, I tested myself again. I reverted back to positive.”

“It was sort of what people are referring to as a Paxlovid rebound,” Fauci said. Over the next day, he began to feel “really poorly,” and “much worse than in the first go-around,” he added.

Court again blocks COVID vaccine mandate for federal workers

The Biden administration’s COVID-19 vaccine mandate for federal employees will remain blocked until at least September after a federal appeals court on Monday agreed to reconsider its previous decision to reinstate the mandate.

The 5th U.S. Circuit Court of Appeals in New Orleans will revisit its April ruling by a three-judge panel that the administration has the legal authority to require federal employees to get vaccinated against COVID-19.

The new injunction will remain until the case can be argued before the full court’s 17 judges, which is tentatively scheduled for the week of Sept. 12.

Children’s Health Defense asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.